Aristeia Capital L.L.C. Invests $763,000 in Tenet Healthcare Corporation $THC

Aristeia Capital L.L.C. purchased a new position in Tenet Healthcare Corporation (NYSE:THC) during the fourth quarter, HoldingsChannel reports. The firm purchased 3,841 shares of the company’s stock, valued at approximately $763,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of THC. NewEdge Advisors LLC boosted its stake in shares of Tenet Healthcare by 6.1% in the 1st quarter. NewEdge Advisors LLC now owns 2,890 shares of the company’s stock worth $389,000 after buying an additional 166 shares during the last quarter. Jones Financial Companies Lllp raised its holdings in Tenet Healthcare by 299.1% in the 1st quarter. Jones Financial Companies Lllp now owns 1,700 shares of the company’s stock worth $229,000 after purchasing an additional 1,274 shares during the period. Sivia Capital Partners LLC bought a new position in Tenet Healthcare in the 2nd quarter worth $290,000. Quantbot Technologies LP bought a new position in Tenet Healthcare in the 2nd quarter worth $65,000. Finally, Amundi raised its holdings in Tenet Healthcare by 4,207.8% in the 2nd quarter. Amundi now owns 27,010 shares of the company’s stock worth $4,652,000 after purchasing an additional 26,383 shares during the period. 95.44% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Tenet Healthcare

In other Tenet Healthcare news, Director Nadja West sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $177.35, for a total transaction of $532,050.00. Following the sale, the director directly owned 24,805 shares of the company’s stock, valued at $4,399,166.75. This trade represents a 10.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director J Robert Kerrey sold 5,638 shares of Tenet Healthcare stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $174.52, for a total value of $983,943.76. Following the completion of the sale, the director directly owned 16,804 shares in the company, valued at $2,932,634.08. This trade represents a 25.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.97% of the stock is owned by company insiders.

Tenet Healthcare Price Performance

NYSE:THC opened at $178.63 on Thursday. The company has a quick ratio of 1.30, a current ratio of 1.36 and a debt-to-equity ratio of 1.96. The business’s 50-day simple moving average is $183.44 and its two-hundred day simple moving average is $199.04. The stock has a market cap of $15.39 billion, a PE ratio of 9.29, a P/E/G ratio of 1.51 and a beta of 1.28. Tenet Healthcare Corporation has a 52 week low of $146.60 and a 52 week high of $247.21.

Tenet Healthcare (NYSE:THC) last posted its quarterly earnings results on Thursday, April 30th. The company reported $4.82 EPS for the quarter, beating analysts’ consensus estimates of $4.21 by $0.61. The business had revenue of $5.37 billion for the quarter, compared to analysts’ expectations of $5.39 billion. Tenet Healthcare had a return on equity of 25.55% and a net margin of 7.94%.The business’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period last year, the firm earned $4.36 earnings per share. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. As a group, analysts forecast that Tenet Healthcare Corporation will post 17.61 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Wells Fargo & Company decreased their target price on Tenet Healthcare from $265.00 to $213.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Royal Bank Of Canada decreased their target price on Tenet Healthcare from $277.00 to $236.00 and set an “outperform” rating on the stock in a report on Friday, May 1st. Wall Street Zen cut Tenet Healthcare from a “strong-buy” rating to a “buy” rating in a report on Monday, May 11th. Morgan Stanley set a $254.00 target price on Tenet Healthcare in a report on Friday, May 1st. Finally, Mizuho raised their target price on Tenet Healthcare from $235.00 to $265.00 and gave the stock an “outperform” rating in a report on Thursday, March 12th. Eighteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Tenet Healthcare presently has an average rating of “Moderate Buy” and an average price target of $244.16.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.